首页> 外文期刊>Mediators of inflammation >Dunye Guanxinning Improves Acute Myocardial Ischemia-Reperfusion Injury by Inhibiting Neutrophil Infiltration and Caspase-1 Activity
【24h】

Dunye Guanxinning Improves Acute Myocardial Ischemia-Reperfusion Injury by Inhibiting Neutrophil Infiltration and Caspase-1 Activity

机译:抑制中性粒细胞浸润和半胱天冬酶-1活性,敦伊省冠新改善急性心肌缺血再灌注损伤

获取原文
获取原文并翻译 | 示例
       

摘要

Acute myocardial infarction is the most serious manifestation of cardiovascular disease, and it is a life-threatening condition. Dunye Guanxinning (DG) is a protective traditional Chinese patent herbal medicine with high clinical efficacy and suitable for the treatment of myocardial infarction. However, the mechanism through which it is beneficial is unclear. In this study, we hypothesized that DG improves acute myocardial ischemia-reperfusion injury by inhibiting neutrophil infiltration and caspase-1 activity. We found that DG administration decreased infarct size and cardiomyocyte apoptosis and improved left ventricular ejection fraction, fractional shortening, end-systolic volume index, end-systolic diameter, and carotid arterial blood flow output in rats. DG administration also improved hemorheological parameters, myocardial damage biomarkers, and oxidative stress indexes. The findings showed that DG administration inhibited neutrophil infiltration and reduced the serum interleukin-1 beta (IL-1 beta) level and myocardial IL-1 beta maturation. Moreover, DG administration inhibited caspase-1 activity and activated adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in rat hearts. These results suggested that DG administration inhibits inflammasome activity and IL-1 beta release through the AMPK pathway. Our findings support the clinical efficacy of DG and partially reveal its mechanism, which is beneficial for understanding the therapeutic effects of this protective traditional Chinese patent drug.
机译:急性心肌梗死是心血管疾病最严重的表现,是一种危及生命的病情。敦伊冠新(DG)是一种保护性传统的中国专利草药,具有高临床疗效,适合治疗心肌梗塞。然而,它是有益的机制尚不清楚。在这项研究中,我们假设DG通过抑制中性粒细胞浸润和Caspase-1活性来提高急性心肌缺血再灌注损伤。我们发现,DG管理降低了梗塞大小和心肌细胞凋亡,改善左心室喷射分数,分数缩短,末端收缩量指数,末端收缩直径和大鼠颈动脉血流输出。 DG管理还改善了血液流变学参数,心肌损伤生物标志物和氧化应激指数。结果表明,DG给药抑制中性粒细胞浸润并降低了血清白细胞介素-1β(IL-1β)水平和心肌IL-1β成熟。此外,DG给药抑制了大鼠心中的Caspase-1活性和活化的腺苷一磷酸酯活化蛋白激酶(AMPK)磷酸化。这些结果表明DG给药抑制炎症活动和IL-1β通过AMPK途径释放。我们的研究结果支持DG的临床疗效,部分揭示其机制,有利于理解这种保护性传统专利药物的治疗效果。

著录项

  • 来源
    《Mediators of inflammation》 |2018年第ptai期|共13页
  • 作者单位

    Shanghai Univ Tradit Chinese Med Inst Interdisciplinary Med Sci Shanghai 201203 Peoples R China;

    Shanghai Univ Tradit Chinese Med Inst Interdisciplinary Med Sci Shanghai 201203 Peoples R China;

    Shanghai Univ Tradit Chinese Med Inst Interdisciplinary Med Sci Shanghai 201203 Peoples R China;

    Shanghai Univ Tradit Chinese Med Inst Interdisciplinary Med Sci Shanghai 201203 Peoples R China;

    Shanghai Univ Tradit Chinese Med Inst Interdisciplinary Med Sci Shanghai 201203 Peoples R China;

    Shanghai Univ Tradit Chinese Med Inst Interdisciplinary Med Sci Shanghai 201203 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 病理学;
  • 关键词

  • 入库时间 2022-08-20 03:50:56

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号